GUJTHEMBSEGujarat Themis Biosyn LtdHighNeutral
Announced Mon, 25 May · 15:07 IST

The Board of Directors at its meeting held today, have inter alia, transacted the following items of business and taken the decisions as under: 1. Approved the Audited Financial Results ....

Pat NegativeEbitda Margin CompressionDebt Equity ThresholdResults View source PDF

GUJTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.8%1-day move
₹363.10
prior close
₹394.10
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.9-1.5-1.0+0.8+16.8+11.8+8.5+8.2+13.7+4.9+7.5+0.2
Up moveDown movePending
AI summary

The board approved audited financial results for Q4 and full year ended March 31, 2026. Total income grew 9.8% to ₹16,825 Lakhs from ₹15,323 Lakhs. However, profit before tax declined 5.3% to ₹6,209 Lakhs (vs ₹6,554 Lakhs), mainly due to significantly higher finance costs (₹295 Lakhs vs ₹36 Lakhs) and doubled depreciation (₹1,292 Lakhs vs ₹537 Lakhs). PAT declined 4.3% to ₹4,668 Lakhs. The company also declared a dividend of ₹0.67 per share and approved a preferential issue of equity shares to non-promoters, subject to shareholder and regulatory approvals. Significant capital expansion is underway with ₹17,253 Lakhs invested in property, plant and equipment during the year.

Likely market impact

PAT declined year-on-year despite revenue growth, indicating margin pressure from higher depreciation and finance costs due to heavy debt-funded expansion. The proposed preferential issue will dilute existing shareholders. Investors should monitor the company's ability to monetize its expansion given the significant increase in borrowings from ₹2,964 Lakhs to ₹12,806 Lakhs.